Long-term effects on growth of an energy-enhanced parenteral nutrition in preterm newborn: A quasi-experimental study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
01
2020
accepted:
18
06
2020
entrez:
7
7
2020
pubmed:
7
7
2020
medline:
15
9
2020
Statut:
epublish
Résumé
To assess the best energy intake in Parenteral Nutrition (PN) for preterm newborns, considering both possible benefits for growth and risk of complications. Quasi-experimental study comparing two cohorts of newborns, receiving Energy-Enhanced vs. Standard PN (Cohort A, from 1st January 2015 to 31 January 2016 and Cohort B from 1st February 2016 to 31 March 2017; respectively) after implementation of a change in the PN protocol. The primary outcome measure was growth at 24 months of life. The PN associated complications were also measured. We enrolled 132 newborns in two Cohorts, similar for prenatal and postnatal clinical characteristics. Although, body weight and length at 24 months of life were significantly higher (p<0.05) in the Cohort A (11.1, 95% CI 10.6 to 11.6 Kg; 85.0 95% CI 83.8 to 86.2 cm) compared with Cohort B (10.4, 95% CI 9.9 to 10.9 Kg; 81.3 95% CI 79.7 to 82.8 cm), body weight and length Z-Score in the first 24 months of life were similar between the two Cohorts. The rate of PN associated complications was very high in both study Cohorts (up to 98% of enrolments). Multivariate analysis showed that length at 24 months was significantly associated with receiving standard PN (cohort A) in the first week of life and on the energy intake in the first week of life. We also found a marginally insignificant association between Cohort A assignment and body weight at 24 months of life (p = 0.060). Energy-enhanced PN in early life has not significant effects on long-term growth in preterm newborns. The high prevalence of PN associated complications, poses concerns about the utility of high energy intake recommended by current guidelines for PN.
Identifiants
pubmed: 32628715
doi: 10.1371/journal.pone.0235540
pii: PONE-D-19-35439
pmc: PMC7337335
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0235540Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Pediatr Res. 2016 Jun;79(6):810-20
pubmed: 26866908
Aliment Pharmacol Ther. 2012 Apr;35(7):782-8
pubmed: 22324448
JAMA. 2012 Feb 22;307(8):795-803
pubmed: 22307571
Clin Nutr. 2018 Dec;37(6 Pt B):2315-2323
pubmed: 30100107
Arch Dis Child Fetal Neonatal Ed. 2008 Sep;93(5):F337-41
pubmed: 18252814
Front Pediatr. 2018 Dec 20;6:408
pubmed: 30619799
Am J Clin Nutr. 2013 Apr;97(4):816-26
pubmed: 23446896
Early Hum Dev. 2016 Sep;100:35-41
pubmed: 27391871
Am J Clin Nutr. 2016 Feb;103(2):635S-47S
pubmed: 26791186
Eur Med J (Chelmsf). 2019 Mar;4(1):20-29
pubmed: 31372499
Acta Paediatr. 2009 Jan;98(1):31-5
pubmed: 18727685
J Pediatr. 2006 Mar;148(3):300-305
pubmed: 16615955
Atherosclerosis. 2017 Nov;266:31-40
pubmed: 28950165
Am J Clin Nutr. 2013 Dec;98(6):1468-74
pubmed: 24025633
Neonatology. 2018;113(3):187-205
pubmed: 29268262
Neonatology. 2018;113(2):100-107
pubmed: 29131014
Arch Dis Child Fetal Neonatal Ed. 1997 Jul;77(1):F4-11
pubmed: 9279175
Clin Nutr. 2018 Dec;37(6 Pt B):2309-2314
pubmed: 30078715
Lancet Glob Health. 2015 Nov;3(11):e681-91
pubmed: 26475015
Acta Paediatr. 2013 May;102(5):471-9
pubmed: 23398476
JAMA Pediatr. 2015 Nov;169(11):1003-10
pubmed: 26348113
Lancet Respir Med. 2017 Jun;5(6):475-483
pubmed: 28522351
Pediatrics. 2008 Nov;122(5):1119-26
pubmed: 18977994
J Perinatol. 2009 Sep;29(9):618-22
pubmed: 19461590
J Perinatol. 2004 Aug;24(8):482-6
pubmed: 15167885
Ital J Pediatr. 2019 Jan 3;45(1):1
pubmed: 30606228
Lancet. 2003 May 24;361(9371):1789-91
pubmed: 12781540
Pediatrics. 2014 Jan;133(1):e120-8
pubmed: 24379229
Ann Nutr Metab. 2017;70(3):236-240
pubmed: 28301849
PLoS One. 2017 Nov 27;12(11):e0186936
pubmed: 29176758